Surgery Versus Stereotactic Radiosurgery in the Treatment of Single Brain Metastasis: A Randomized Trial

Eligible patients will be randomized to either conventional surgery or stereotactic radiosurgery, or participate as a separate group of the study, if they refuse randomization. At the time of diagnosis, patients may be given dexamethasone which will be continued throughout treatment then discontinued in a tapered fashion. Patients with supratentorial tumors and a history of seizures may be treated with anticonvulsants. For patients in the surgical group, surgery will be performed using standard techniques and any necessary intraoperative adjuncts. For patients in the stereotactic radiosurgery group, stereotactic radiosurgery will be delivered using the modified linear accelerator and multiple non-coplanar converging arcs. The dose prescribed will be dependent on the volume treated. Changes in patients' clinical courses will be treated as medically necessary. Should metastases recur or progress at the primary intracerebral site or at a distant intracerebral site, patients who received radiosurgery remain eligible for surgical resection and patients who received conventional surgery may undergo repeat resection or radiosurgery. Whole brain radiotherapy may be given to patients who demonstrate local or distant recurrence and can be given as the primary therapy or as adjunctive therapy. The WBRT dose will be 30 Gy delivered in ten fractions.

Inclusion criteria

• Age 16 years and older;
• Documented diagnosis of cancer within 5 years (except for patients with unknown primary);
• Newly diagnosed single brain metastases as determined by MRI;
• Candidacy for both conventional surgical resection as well as stereotactic radiosurgery;
• Karnofsky Performance Score > 70;
• Life expectancy of at least 4 months;
• Signature of the approved consent form.

Exclusion criteria

• Prior radiation therapy to the brain;
• Evidence of leptomeningeal disease;
• Need for immediate treatment to prevent neurological deterioration;
• Extremely radiosensitive primary tumor;
• Prior radioiodine (for thyroid metastases);
• Pregnancy or lactation.